CSIR in the news..

An aggregation of news on the web about CSIR and its laboratories

Archive for the ‘IMTECH’ Category

Nostrum Pharmaceuticals, LLC Licenses Clinical Development and Worldwide Commercialization Rights From IMTECH, India, for Novel, Next-Generation Thrombolytics With Clot Specific Activation and Re-occlusion Prevention Properties

24 November 2010

NEW BRUNSWICK, N.J: Nostrum Pharmaceuticals, LLC (“Nostrum”), a privately held pharmaceuticals company based in New Brunswick, New Jersey, announced today its licensing agreement with Institute of Microbial Technology (“IMTECH”), Chandigarh, India, a research institute under Council of Scientific and Industrial Research (“CSIR”), a Government of India organization.  Pursuant to such agreement, Nostrum will in-license next generation thrombolytics from IMTECH for clinical development and worldwide commercialization.

Nirmal Mulye, Ph.D., President of Nostrum, said, “These novel, next generation thrombolytics are clot specific plasminogen activator proteins, and each one of these molecules has a uniquely different value-added properties such as longer half-life in blood circulation and re-occlusion prevention during heart attack.  Moreover, these unique properties of the molecules will help to effectively mitigate a number of systemic side effects, such as bleeding, usually associated with the prevalent thrombolytic protein molecules in the market today.”  Dr. Mulye further said, “Our collaboration with CSIR is an example of successful public-private partnership.  This is our third collaboration with IMTECH/ CSIR.  Clearly they have been developing world-class technologies and setting an example of pursuing commercially viable innovations.”

These new molecules were invented at IMTECH in the laboratory headed by Girish Sahni, Ph.D., who is also the director of IMTECH.  Dr. Sahni said, “Re-occlusion of the blood vessel after thrombolytics treatment remains one of the main cause for patient death after the heart attack and continues to be both a practical and scientific challenge to reckon with.”  Dr. Sahni added, “My group at IMTECH had been working for a very long time to come up with an approach that will resolve the issue of blood vessel re-occlusion after thrombolytics treatment.  I am glad that one of our new thrombolytic molecules has shown that promise in the laboratory experiments.  Based on these results we are confident that it will develop into a world class drug with a most sought after property of not only clot specificity of activation but also re-occlusion prevention.”  Dr. Sahni further added, “Collaborating with Nostrum over the years has been a very fulfilling experience.  They have demonstrated a true commitment to take forward our collaborations as seen by the remarkable pace at which they have taken forward the development of our first thrombolytic Clot Specific Streptokinase (CSSK).”…..

Read more: http://www.sunherald.com/2010/11/24/2666186/nostrum-pharmaceuticals-llc-licenses.html#ixzz16GJTZG22

Written by csirindia

November 25, 2010 at 9:12 am

Posted in IMTECH

CSIR’s molecule success gives a big boost to public research

18 November 2010

A key molecule to treat heart disease—developed at a government lab and slated for the market in 2012 if human trials are successful—could change the way public research institutes approach drug discovery.

The clot-specific streptokinase has cleared crucial trials on monkeys in the US, according to Girish Sahni, director of Chandigarh-based Institute of Microbial Technology (IMTech), where the drug was developed.

“If the next phase III (human) trials are successful by 2012, it would be a great success,” Sahni said.

IMTech, which operates under the Council of Scientific and Industrial Research (CSIR), exclusively licensed the streptokinase molecule to Nostrum Pharmaceuticals Llc, a US-based firm, in 2006, in a first-of-its-kind deal involving publicly-funded labs.

Although the licensing fee of Rs.25 crore is minuscule compared with the billions a blockbuster drug earns for pharma firms, it is for the first time that a state-run lab has tried extracting a relatively higher price for a molecule it developed.

“Typically, we’ve never got more than Rs.5-10 crore for licensing molecules,” said G.S. Prasad, an IMTech scientist associated with streptokinase’s promotional efforts. “So this is a big and encouraging deal that could change the dynamics of molecule development in public labs.”

CSIR, India’s largest scientific organization, has developed several drugs in its 68 years of existence, but has mostly given them out to local companies on a non-exclusive basis. This meant it rarely earned much money from licensing fees, considered the mainstay of research and development firms.

Prasad said drug companies in India generally expect state research organizations to give away molecules for paltry sums. “They say, you are publicly funded. You have no profit targets to meet. So why do you need money?” he said. “That mindset has to change.”

Sahni said CSIR, which holds the largest number of patents in the country, spends a substantial amount of money in filing and maintaining them.

“We don’t have to make money from everything, but high-value patents ought to generate revenues,” he said. “That’ll only help better research and benefit the country.”

Although the new molecule had been licensed to a US firm, it is aimed as a lower-cost product.

“The current state-of-the-art called TPA (tissue plasminogen activator) costs Rs.50,000 for a single injection,” Sahni said. “Our product is also a single shot and will be less than Rs.10,000. So exclusive licensing doesn’t necessarily mean exorbitant prices.”

Experts say medical treatment isn’t confined to chemical drugs and the future could belong to biologics, which includes vaccines and recombinant DNA therapies that promise safer and more effective solutions.

“It’s relatively difficult to spin off a generics industry on biologics than it is to develop chemical drugs,” said Vinay S., a molecular biologist at the University of Delhi. “And that’s largely because of the science and manufacturing process of biologics.”…….

Read more: http://www.livemint.com/2010/11/17211504/CSIR8217s-molecule-success.html?atype=tp

Written by csirindia

November 18, 2010 at 8:31 am

Posted in IMTECH

‘Work on for new vaccine to fight TB’

10 August 2010

NAGPUR: India tops the world, but sadly for the dreaded disease called tuberculosis. Millions die every year. It’s a cause for concern as in developed countries, the disease has been completely eradicated. A study done in Chennai revealed how the BCG vaccine used to immunise tuberculosis has failed.

“The BCG vaccine has limited machinery to offer protection for children, but by the time the child becomes an adult, the immune memory dies and the adult is no longer protected from the disease.” said Dr Javed N Agrewala, guest speaker from IMTECH, Chandigarh.

“We are working to create a new vaccine against tuberculosis by trying to supplement memory enhancing cells which are called ‘cytokines’. These cells will enhance the human immune response thus making the vaccine last longer. This will lead to a drastic reduction in tuberculosis cases and its spread. Although the prospect is promising, the vaccine is still in its experimental stages,” added Agrewala……….

Read more: ‘Work on for new vaccine to fight TB’ – Nagpur – City – The Times of India http://timesofindia.indiatimes.com/city/nagpur/Work-on-for-new-vaccine-to-fight-TB/articleshow/6285286.cms#ixzz0wALgil6r

Written by csirindia

August 10, 2010 at 7:55 am

Posted in IMTECH

Venus Remedies-Imtech to develop typhoid detection kits

04 May 2010

NEW DELHI:  Chandigarh-based Venus Remedies Ltd, a research and development driven pharmaceutical manufacturing company has tied up with the Institute of Microbial Technology (Imtech), a renowned research centre of the Council of Scientific and Industrial Research (CSIR), and Department of Microbiology, Panjab University, to jointly develop a diagnostic kit for typhoid. The kit is expected to bring down the detection time of the disease from 48 hours (from conventional Vidal test) to just few minutes.

“The kit is likely to be in market by 2013. The project has got a lot of social importance attached to it as world-over typhoid affects about 17 million people annually, causing nearly 600,000 deaths. Most of the deaths are caused due to a lack of early detection of the disease. Venus has the mandate to market this kit world over after conducting necessary trials,” said director-research at Venus Remedies Ltd Manu Chaudhary………Read complete news item……..

Written by csirindia

May 4, 2010 at 8:49 am

Posted in IMTECH

Venus Remedies in pact with IMTECH

03 May 2010

MUMBAI: Venus Remedies Ltd has informed BSE that the company has tied up with IMTECH, a renowned research centre of the Council of Scientific and Industrial Research and the Department of Microbiology, Punjab University, to jointly develop a diagnostic k it for typhoid. According to the company, the kit is expected to bring down the detection time of the disease from 48 hours (from conventional vidal test) to just few minutes.

Source: http://www.thehindubusinessline.com/blnus/02031001.htm

Written by csirindia

May 4, 2010 at 8:38 am

Posted in IMTECH

DBT looks for pharma firms to commercialise cholera vaccine

06 April 2010

Department of Biotechnology (DBT) has started scouting for industrial partner to licence and commercialise a live, oral cholera vaccine (IOCV) strain, with a view to make an affordable vaccine available in domestic and overseas markets.

The recombinant oral vaccine is based on VA1.3 strain on V cholerae and has been developed through a multi-centric approach. The vaccine was tested for its safety in phase – I clinical trials and was found to be safe. The extended phase-I/phase-IIa clinical trial recently completed by SAS, Kolkata and SGPGIMS, Lucknow has shown good immunological response, sources said.

So far, about 100 volunteers in the age of 20-30 years have been inducted in the phase-IIa trials. Data from volunteers showed eight-fold rise in 42 per cent of the cases; two-fold rise in 33 per cent and no rise in 25 per cent. In addition, preparation around Kolkata for phase-III clinical trial has been initiated in terms of determining the base-line antibody levels in local population. Concurrently, IMTECH, Chandigarh is making attempts to scale up of VA1.3 strain of Vibrio cholerae in LB medium. After several attempts using a semi-synthetic medium, a healthy growth of V.cholerae VA1.3, has been obtained. The cells were found to be both physiologically and genetically stable……Read complete news item……

Written by csirindia

April 6, 2010 at 10:26 am

Posted in IMTECH

Alex Bateman Wins 2010 Benjamin Franklin Award

01 April 2010

The Bioinformatics Organization has named Alex Bateman, a senior investigator at the Wellcome Trust Sanger Institute in Cambridge, UK, as the winner of the 2010 Benjamin Franklin Award.

Bateman told Bio-IT World he was delighted to win the award. “I strongly believe that open biologically databases are essential to the development of science and technology. This award is only possible due to the tireless work of our biocurators who make the mass of sequence data understandable. Biocurators really are the unsung heroes of molecular biology.”

Bateman was selected from a strong group of finalists that included Don Gilbert (Indiana University), David Lipman (NCBI), John Quackenbush (Harvard School of Public Health), and G.P.S. Raghava (Institute of Microbial Technology). Bateman is the third scientist from the twin campuses of the Sanger Institute and European Bioinformatics Institute to win the award, following in the footsteps of Ewan Birney and Michael Ashburner. He will receive his award from bioinformatics.org president Jeff Bizzaro and give a free lecture on April 21 at the Bio-IT World Conference & Expo in Boston……Read complete news item…….

Written by csirindia

April 6, 2010 at 9:51 am

Posted in IMTECH

Clot-busters awaiting a booster shot

leave a comment »

09 February 2010

By Seema Singh

CHANDIGARH: Spread over a 25-acre campus, the Institute of Microbial Technology (IMTech) could well be nicknamed the poor man’s clot-buster lab. That may not be fair because the institute does more research even while it manages India’s micro-organism bank, but it is the blood clot-buster molecules coming out of the campus that are demonstrating, for the first time, that drugs can come out of government labs too.

In the last three years, IMTech, part of the Council of Scientific and Industrial Research, has clinched licensing deals worth at least Rs50 crore for molecules that produce a variety of clot dissolving drugs for treating myocardial infarction and pulmonary embolism, blockage of the lung artery. Now it’s ready with the next-in-class clot buster—pegylated streptokinase, a polyethylene glycol-(PEG) fortified enzyme that liquefies blood clots.

Still, director Girish Sahni, a streptokinase researcher himself who proudly displays two different vials of streptokinase that came out of his lab, looks a little impatient. Given India’s cardiac disorder burden, he is somewhat racing against time to take his next molecule to the market, a much superior drug that would considerably reduce the price of its equivalent, selling for as much as Rs50,000 a dose. “We are doing it slowly and surely, but we’d like to do it energetically and faster,” he says.

For that, he needs funds and an institutional system that would give people like him money and the freedom to do, and even outsource, science. “Scientists and groups who have demonstrated excellence should be given a carte blanche. Somebody should, say, take $20 million and run with it,” Sahni says, rather wistfully.

In 2006, he licensed clot-specific streptokinase to a US-based start-up Nostrum Pharmaceuticals Llc, which did the primate trials of the molecule in the US, since monkey studies are hardly done in India. Experts say looking for such partners takes time. Moreover, out-licensing at an early stage is also meagrely rewarding, financially. “Give me $2-3 million and I’d do such studies in six months,” he adds……Read complete news item……

Written by csirindia

February 10, 2010 at 2:50 pm

Posted in IMTECH

Scientists call for greater research on infectious diseases at meet

leave a comment »

23 January 2010

CHANDIGARH: “Infectious diseases pose a continuous challenge to public health around the world. There is an unending war between anti-microbials and the resistance of human body that grows over time,” said Dr Barry R Bloom, a professor at Harvard University, USA.

Delivering the inaugural lecture at the three-day international conference on ‘Understanding and Managing Pathogenic Microbes 2010’ at the Institute of Microbial Technology (IMTECH) in Chandigarh on Friday, Dr Bloom called for more public spending on the research and treatment of infectious diseases in the developing countries…..Read complete news item……

Written by csirindia

January 25, 2010 at 9:27 am

Posted in IMTECH

Dragon emission cuts bite pharma industry

leave a comment »

07 December 2009

By Shimona Kanwar

CHANDIGARH: The assurance of cutting greenhouse gas emissions by China — a source of cheap raw material — has sent jitters across the pharmaceutical industry, which apprehends that it will lead to drug rates shooting up.

Difficulty in obtaining cheap raw material for chemical synthesis from China has already resulted in price escalation of many drugs. The cost of Heparin, a life-saving injection used to prevent blood clot in kidney transplant and heart surgery has jumped from Rs 32 to Rs 120 in an year.

……..Agreeing that the market is driven by economic conditions and the industry shall make up for the loss from the consumer, Girish Sahni, director, Institute of Microbial technology, said, “Scientists must be motivated to come up with newer technologies so that we are able to manufacture chemicals which are imported from places like China. There is a need for the government to subsidise these chemicals and raw materials at this time.” Though the raw material from China is not have approved standard, the buyers have been making a beeline for cheap material……Read complete news item……

Written by csirindia

December 7, 2009 at 3:50 pm

Posted in IMTECH